Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.

导出 LinkOut

翻译打印收藏纠错

作者： A,Planagumà ^[1] ; T,Domènech ^[2] ; M,Pont ^[3] ; E,Calama ^[3] ; V,García-González ^[2] ; R,López ^[2] ; M,Aulí ^[4] ; M,López ^[5] ; S,Fonquerna ^[6] ; I,Ramos ^[2] ; J,de Alba ^[3] ; A,Nueda ^[2] ; N,Prats ^[4] ; V,Segarra ^[5] ; M,Miralpeix ^[3] ; M D,Lehner ^[3]

作者单位： Respiratory Therapeutic Area-Discovery, Almirall, R&D Centre, Laureà Miró 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. Electronic address: anna.planaguma@almirall.com. ^[1] Biological Reagents and Assay Development Screening, Almirall, R&D Centre, Laureà Miró 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. ^[2] Respiratory Therapeutic Area-Discovery, Almirall, R&D Centre, Laureà Miró 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. ^[3] Pathology and Predictive Toxicology Section, Almirall, R&D Centre, Laureà Miró 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. ^[4] Computational and Structural Drug Discovery Department, Almirall, R&D Centre, Laureà Miró 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. ^[5] Medicinal Chemistry Department, Almirall, R&D Centre, Laureà Miró 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. ^[6]

关键词 9841667)9865554)COPD Chemokine receptor Chemotaxis Lung inflammation Neutrophils SB265610 (PubChem CID SCH527123 (PubChem CID Severe asthma